Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 28, Issue 2, Pages 925-930Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2015.03.039
Keywords
Graft-versus-host disease; GVHD; Induced regulatory T cell iTreg; CD39; Inflammatory cytokine
Categories
Funding
- International Collaboration Foundation of Jiangsu Province [BZ2011041, BK2009439, ZX05 200904, WS2011106]
- Ministry of Health for health research [201302009]
- Development of Innovative Research Team in First Affiliated Hospital of NJMU
- National Natural Science Foundation of China [81273262, 81210108017, 81100270, 81070380]
Ask authors/readers for more resources
CD4(+)CD25(+)FoxP3(+) regulatory T (Treg) cells which consist of naturally occurring Treg (nTreg) and induced Treg (iTreg) cells are associated with the maintenance of immune homeostasis. Previous studies were focused on their potential to ameliorate graft-versus-host disease (GVHD) in human and mice. CD39 is a surface marker both expressed on CD4(+)CD25(-) T cells and Treg cells. CD39(+) Treg cells demonstrate stronger suppressive ability compared to conventional Treg cells. However, whether the potential of CD39(+) naive T cells induced Treg cells is different from conventional naive T cells induced Treg cells in vivo and vitro remains to be inconclusive. Here we demonstrate that CD39(+) iTreg cells show enhanced proliferation and suppressive ability as well as lower inflammatory cytokines compared to CD39(-) iTreg cells. To conclude, our findings demonstrate that CD39(+) iTreg cells acquire high suppressive capacity in vitro and vivo, and this may provide a new insight into Treg cell therapy in GVHD clinical trials. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available